[A21-19] Durvalumab (small cell lung cancer) - Addendum to Commission A20-87
Last updated 01.04.2021
Project no.:
A21-19
Commission:
Commission awarded on 09.02.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Extensive-stage small cell lung cancer (ES-SCLC)
Result of dossier assessment:
unchanged after addendum:
- Men: hint of considerable added benefit.
- Women: hint of added benefit; extent "non-quantifiable", at most "considerable".
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-87 | Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021.04.01 A G-BA decision was published.